Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation

NCT07397351 | Recruiting Phase 2 DMC

• 1 other identifier: CTARE25/II
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, randomized, multicenter Phase II clinical study designed to evaluate the cardioprotective effect, to determine the optimal dosages and duration of inhalation, and to assess the clinical safety of the medicinal product Aroxxen® in patients undergoing elective percutaneous coronary intervention (PCI) with stent implantation. Patients who undergo elective PCI are at risk of myocardial injury associated with the procedure. The study aims to assess whether inhalation of Aroxxen®, administered during the procedure and after it, can reduce markers of myocardial damage and improve clinical outcomes, while maintaining an acceptable safety profile. Eligible patients will be randomized to receive inhalation of Aroxxen® according to the study protocol or standard therapy without inhalation, depending on the assigned group. The study includes multiple centers and compares different dosing regimens and durations of inhalation in order to identify optimal treatment parameters. Safety will be evaluated by monitoring adverse events, vital signs, and clinical laboratory parameters throughout the study period. The results of this study are intended to provide data on the safety and potential cardioprotective effects of Aroxxen® and to support further clinical development.

Conditions

Coronary Artery Disease

Keywords

Myocardial Injury; Percutaneous Coronary Intervention; Stent Implantation; Cardioprotection

Outcome Measures

Primary Outcomes (1)

• Incremental area under the concentration-time curve (iAUC) of high-sensitivity troponin I (hs-cTnI)

  The individual incremental area under the concentration-time curve (iAUC) of high-sensitivity troponin I is calculated for each participant based on serial venous blood measurements obtained at baseline before the start of inhalation and at 4 hours, 12 hours, and 24 hours after the start of inhalation.

  From baseline before the start of inhalation to 24 hours after the start of inhalation (with assessments at 4, 12, and 24 hours).

Study Arms (3)

Aroxxen® Inhalation, Composition Variant 1

EXPERIMENTAL

Patients receive inhalation of the investigational medicinal product Aroxxen® (composition variant 1) during and after elective percutaneous coronary intervention with stent implantation, according to the study protocol.

Drug: Aroxxen

Aroxxen® Inhalation, Composition Variant 2

EXPERIMENTAL

Patients receive inhalation of the investigational medicinal product Aroxxen® (composition variant 2) during and after elective percutaneous coronary intervention with stent implantation, according to the study protocol.

Drug: Aroxxen

Standard Care (No Aroxxen® Inhalation)

NO INTERVENTION

Patients undergo elective percutaneous coronary intervention with stent implantation without additional inhalation of the investigational medicinal product.

Interventions

Aroxxen DRUG

Aroxxen® is an investigational medicinal product administered by inhalation during and after elective percutaneous coronary intervention in accordance with the study protocol.

Aroxxen® Inhalation, Composition Variant 1; Aroxxen® Inhalation, Composition Variant 2

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

1. Presence of coronary artery disease with stenosis of one or more coronary arteries requiring elective percutaneous coronary intervention for stent implantation (including patients with stable angina pectoris, Canadian Cardiovascular Society functional class II-IV, and patients with post-infarction or atherosclerotic cardiosclerosis with or without angina). 2. Clinically and/or hemodynamically significant coronary artery stenosis confirmed by coronary angiography, with an indication for percutaneous coronary intervention with stent implantation. 3. Age 50 to 80 years inclusive at the time of signing informed consent. 4. Baseline high-sensitivity troponin I within the laboratory reference range, excluding acute coronary syndrome. 5. Written voluntary informed consent obtained after the participant has received full information about the study objectives, methods, risks, and potential benefits. 6. Willingness and ability to comply with all study procedures and visits specified in the protocol.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Research Institute of Geroprotective Technologies: lead

Study Sites (1)

City Multidisciplinary Hospital No. 2

Saint Petersburg, Russia

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 2, 2026
• First Posted: February 9, 2026
• Study Start: March 5, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: May 6, 2026

Record last verified: 2026-04

Locations

RU (1)